The hollow fibre assay as a model for in vivo pharmacodynamics of fluoropyrimidines in colon cancer cells
Open Access
- 19 December 2006
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 96 (1) , 61-66
- https://doi.org/10.1038/sj.bjc.6603507
Abstract
The Hollow Fibre Assay (HFA) is usually applied as an early in vivo model for anti-cancer drug screening, but is potentially an excellent model for short-term in vivo pharmacodynamic studies. We used the model to study the in vivo role of thymidine phosphorylase/platelet-derived endothelial cell growth factor (TP/PD-ECGF) in the cytotoxicity and pharmacodynamics of TAS-102 in colon cancer cells. TAS-102 is a new oral drug formulation, which is composed of trifluorothymidine (TFT) and thymidine phosphorylase inhibitor (TPI), which prevents TFT degradation. We compared the activity with Xeloda (capecitabine), which is activated by TP into 5FU. Hollow fibres filled with human Colo320 or Colo320TP1 colorectal cancer cells with deficient or high TP expression, respectively, were implanted subcutaneously (s.c.) at both flanks of BALB/c mice. The mice were treated orally over 5 days with TAS-102, TFT alone, 5′DFUR±TPI or capecitabine at their maximum tolerated dose (MTD). The cells were retrieved from the fibres and assayed for growth (MTT assay), cell cycle distribution (flow cytometry) and apoptosis induction (FragEL method). TAS-102 induced considerable growth inhibition (50%, P8-fold), which was more pronounced in Colo320 than in Colo320TP1. Again, omission of TPI neutralised the effect of TAS-102. Similarly, 5′DFUR and capecitabine induced a significant G2M-phase arrest (up to 45%) in the Colo320TP1 cell line, but less pronounced in the parental Colo320. Addition of TPI to 5′DFUR reduced this effect to control levels. Also induction of apoptosis was reduced in the presence of TPI. The data demonstrated that the HFA is excellently suited for studying short-term pharmacodynamic effects of fluoropyrimidines in vivo. TAS-102 is only effective in inducing cytotoxicity when systemic TPI is present, but acts against both low and high TP expressing colon cancer cells, while 5′DFUR needs cellular TP to exert significant activity.Keywords
This publication has 46 references indexed in Scilit:
- Oral capecitabine: Bridging the Atlantic divide in colon cancer treatmentSeminars in Oncology, 2005
- Characterization of the Hollow Fiber Assay for the Determination of Microtubule DisruptionIn vivoClinical Cancer Research, 2004
- Clonogenic assay with established human tumour xenograftsEuropean Journal Of Cancer, 2004
- The hollow fibre model in cancer drug screeningEuropean Journal Of Cancer, 2004
- Involvement of cell cycle control in bleomycin‐induced mutagen sensitivityEnvironmental and Molecular Mutagenesis, 2002
- In vivo cultivation of tumor cells in hollow fibersLife Sciences, 1995
- Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testingEuropean Journal of Cancer and Clinical Oncology, 1991
- A Critical Appraisal of the Predictive Value of In Vitro Chemosensitivity AssaysJNCI Journal of the National Cancer Institute, 1990
- New Colorimetric Cytotoxicity Assay for Anticancer-Drug ScreeningJNCI Journal of the National Cancer Institute, 1990
- Colony assay with human tumor xenografts, murine tumors and human bone marrow. Potential for anticancer drug developmentEuropean Journal of Cancer and Clinical Oncology, 1987